Literature DB >> 22057490

Intracutaneous ALA photodynamic therapy: dose-dependent targeting of skin structures.

Fernanda H Sakamoto1, Apostolos G Doukas, William A Farinelli, Zeina Tannous, Yao Su, Nicholas A Smith, David Zurakowski, R Rox Anderson.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) using topical aminolevulinic acid (ALA) depends on local drug uptake, metabolism to porphyrins, and depth of light penetration using different wavelengths. Topical ALA-PDT has limited depth of drug penetration. We studied induced porphyrin distribution and PDT after intradermal ALA administration using different drug concentrations followed by high-fluence red light irradiation.
MATERIALS AND METHODS: Intradermal injections (∼2 mm deep) of ALA concentrations from 0.0005% to 1% were studied in swine to evaluated porphyrin fluorescence before PDT and clinical and histological damage 24 hours after PDT. Porphyrin accumulation was measured by fluorescence microscopy of frozen section. PDT was performed 3 hours after intradermal injections using a 635 nm LED array at a fluence of 200 J/cm2 . Skin responses to PDT were observed grossly and by histology (blind evaluation).
RESULTS: Intradermal ALA caused porphyrin accumulation in epidermis, hair follicles (HF), sebaceous glands (SG), sweat glands (eccrine glands, EG and apocrine glands, AG), and subcutaneous fat. Significant differences of fluorescence intensity were observed between different skin structures (P < 0.05), but there was no significant difference comparing HF to SG; epidermis with either HF or SG; and dermis with fat (P > 0.05). Intradermal ALA is potent. ALA concentrations ≥0.25% followed by red light exposures caused a very intense vascular PDT reaction. Moderate doses of injected ALA concentration (∼0.06%), selectively targeted EG. Low doses (≤0.016%) targeted fat; producing fat necrosis with minimal inflammation, manifested both clinically and histologically. In contrast to topical ALA-PDT, intradermal ALA-PDT can effectively photosensitize deep skin structures.
CONCLUSION: Potentially, intradermal ALA-PDT using various ALA concentrations may be useful for treating vascular lesions (malformations, hemangiomas, tumors), EG/AG disorders, fat or deep targets in skin.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057490     DOI: 10.1002/lsm.21073

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  5 in total

1.  Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema.

Authors:  Srivalleesha Mallidi; Sriram Anbil; Seonkyung Lee; Dieter Manstein; Stefan Elrington; Garuna Kositratna; David Schoenfeld; Brian Pogue; Steven J Davis; Tayyaba Hasan
Journal:  J Biomed Opt       Date:  2014-02       Impact factor: 3.170

2.  Superficial hemangioma is better treated by topical 5-aminolevulinic followed by 595-nm pulsed dye laser therapy rather than 595-nm laser therapy alone.

Authors:  Ming Zeng; Songke Shen; Wei Chen; Chunjun Yang; ShengXiu Liu
Journal:  Lasers Med Sci       Date:  2017-08-16       Impact factor: 3.161

3.  Current Advances in 5-Aminolevulinic Acid Mediated Photodynamic Therapy.

Authors:  Connor Thunshelle; Rui Yin; Qiquan Chen; Michael R Hamblin
Journal:  Curr Dermatol Rep       Date:  2016-07-13

Review 4.  Current trends in needle-free jet injection: an update.

Authors:  Daniel Barolet; Antranik Benohanian
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-05-01

5.  An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.

Authors:  Lizette Anayo; Anette Magnussen; Alexis Perry; Mark Wood; Alison Curnow
Journal:  Lasers Surg Med       Date:  2018-03-31       Impact factor: 4.025

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.